In stock
Carfilzomib SPC 60 Powder for injection Vial
In stock
Only 1 left
SKU
10331014345
Carfilzomib 60 mg powder for injection is a prescription medication used to treat multiple myeloma. It acts as a proteasome inhibitor, targeting cancer cells to induce their death. Administered intravenously by a healthcare professional, it's a vital part of advanced cancer treatment. Regular monitoring and adherence to physician's instructions are crucial for safe and effective use.
Product Overview
Carfilzomib 60 mg powder for injection is a potent antineoplastic agent. It is primarily used in the treatment of relapsed or refractory multiple myeloma. This medication works by selectively inhibiting the proteasome, a critical enzyme complex in cell regulation. This action leads to the accumulation of ubiquitinated proteins, ultimately inducing apoptosis in myeloma cells.Key Benefits
- Targets specific proteasome activity essential for myeloma cell survival.
- Indicated for patients with multiple myeloma who have received at least one prior therapy.
- Can be used as a single agent or in combination with other anti-myeloma treatments.
- A crucial therapeutic option in the management of advanced multiple myeloma, contributing to disease control.
How to Use
- Carfilzomib is administered as an intravenous infusion by a qualified healthcare professional.
- The dosage and treatment schedule are determined by your physician based on your medical condition, body surface area, and response to therapy.
- Before administration, the powder for injection must be reconstituted with sterile water and then further diluted in an appropriate intravenous solution.
- Patients typically receive premedication and adequate hydration before and during Carfilzomib infusions to minimize potential side effects.
- Strict adherence to the prescribed dosing regimen and careful monitoring by your healthcare team are essential during treatment.
Caution & Warnings
- Infusion-related reactions may occur; monitor patients during and after infusion.
- Cardiac toxicity, including heart failure and ischemia, has been reported; regular cardiac monitoring is advised, especially in patients with pre-existing heart conditions.
- Pulmonary hypertension and dyspnea can develop; seek immediate medical attention for new or worsening respiratory symptoms.
- Renal toxicity, including acute renal failure, may occur; monitor renal function tests regularly.
- Thrombocytopenia (low platelet count) is a common adverse effect; complete blood counts should be monitored frequently.
- Risk of tumor lysis syndrome (TLS) and hepatic toxicity; monitor laboratory parameters accordingly.
- Embryo-fetal toxicity: Carfilzomib can harm a developing fetus. Patients of reproductive potential must use effective contraception during and after treatment.
- Peripheral neuropathy has been observed; evaluate for new or worsening symptoms.
Ingredients
- Active Ingredient: Carfilzomib 60 mg per vial.
- Excipients: Commonly include Sulfobutylether Beta-Cyclodextrin Sodium (SBECD), Citric Acid, Sodium Hydroxide (for pH adjustment).
Product Details
- Form: Powder for injection.
- Strength: 60 mg.
- Package Type: Single-use vial.
- Administration Route: Intravenous.
- Therapeutic Class: Antineoplastic Agent, Proteasome Inhibitor.
| Gtin | 3112200377 |
|---|---|
| Recommended Sale Price | 3441.2 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | CARFILZOMIB |
| SFDA Reg. No | 3112200377 |
| IBC | 3112200377 |
| Drug Type | Prescription |
| Scientific Name | Carfilzomib |
| Strength | 60 |
| Strength Unit | mg |
| Form | Powder for injection |
| Admin Route | Intravenous |
| Size | 1 |
| Size Unit | Vial |
| Package Types | Vial |
| Package Size | 1 vial |
| Storage conditions | Store in a refrigerator (2°C - 8°C). Do not freeze. |
| Refrigerator Storage | Yes |
Products you might like
